Research to Develop Next Generation of TB Vaccines

Moleculin Biotech WP1122 Portfolio Compound, WP1096, Selected for NIAID-Funded Animal Studies as Novel Potential Antiviral

Link Type
Funded-research
Media Type
Article
Publish or Event Date
Link URL
https://moleculin.com/moleculin-biotech-wp1122-portfolio-compound-wp1096-selected-for-niaid-funded-animal-studies-as-novel-potential-antiviral/
Research Institution
Moleculin Biotech
Short Title
Moleculin Biotech WP1122 Portfolio Compound, WP1096, Selected for NIAID-Funded Animal Studies as Novel Potential Antiviral
Content Coordinator
Claudia Wair
Content Manager
Catey Laube Macdonald

Placenta-On-a-Chip Mimics Nutrient Exchange Between Mother-Fetus

Expertise in Gut Barrier Dysfunction Earns UTHSC Researcher Two Awards Totaling $5 Million

Link Type
Funded-research
Media Type
Article
Publish or Event Date
Link URL
https://news.uthsc.edu/expertise-in-gut-barrier-dysfunction-earns-uthsc-researcher-two-awards-totaling-5-million/
Research Institution
University of Tennessee Health Science Center
Short Title
Expertise in Gut Barrier Dysfunction Earns UTHSC Researcher Two Awards Totaling $5 Million
Content Coordinator
Claudia Wair
Content Manager
Catey Laube Macdonald

Newly Funded Effort Aims for Vaccine against Valley Fever

UCI Awarded $13.8 Million Federal Contract to Profile Lipid Nanoparticles

Link Type
Funded-research
Media Type
Article
Publish or Event Date
Link URL
https://news.uci.edu/2022/09/26/uci-awarded-13-8-million-federal-contract-to-profile-lipid-nanoparticles/
Research Institution
University of California, Irvine
Short Title
UCI Awarded $13.8 Million Federal Contract to Profile Lipid Nanoparticles
Content Coordinator
Claudia Wair
Content Manager
Catey Laube Macdonald

Researchers from NAU, Washington Tackling an Elusive Valley Fever Vaccine

The Longer the Bootcamp, the Better the Antibodies

How Human Cells Become Zika Virus Factories

Phase 1/2 Open-label Trial of Safety and Immunogenicity of Recombinant Varicella Zoster Virus Vaccine (RZV) in People with HIV Who Have a CD4 Count < 300 or ≥ 300 and a Healthy Control Population

The purpose of this study it to learn how Shingrix affects the immune response in people with HIV.

Contact Information

Volunteer or get more information 
Toll free: 1-800-411-1222 
TTY: 1-866-411-1010 
Se habla español 
  
Email: prpl@mail.cc.nih.gov  

Subscribe to